Inventiva (NASDAQ:IVA) Price Target Cut to $9.00 by Analysts at Guggenheim

Inventiva (NASDAQ:IVA) had its price objective trimmed by Guggenheim from $12.00 to $9.00 in a research report report published on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other brokerages also recently weighed in on IVA. TD Cowen began coverage on Inventiva in a report on Friday, February 21st. They set a “buy” rating and a $10.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $13.00 target price on shares of Inventiva in a research note on Friday, March 28th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Inventiva presently has a consensus rating of “Moderate Buy” and an average target price of $12.00.

Inventiva Stock Up 1.7 %

IVA stock opened at $3.07 on Friday. The firm has a 50-day moving average of $2.77 and a two-hundred day moving average of $2.51. Inventiva has a one year low of $1.53 and a one year high of $3.98.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.